| Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. | |
| | |
MedLine Citation:
|
PMID: 20167845 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
RATIONALE: Cytomegalovirus pneumonitis is one of the most prevalent opportunistic infections after lung transplantation. Early studies reported that cytomegalovirus pneumonitis was a risk factor for chronic allograft dysfunction. More recently, in the era of routine prophylaxis and ganciclovir treatment, the adverse impact of treated cytomegalovirus pneumonitis on bronchiolitis obliterans syndrome has been challenged. Objectives: We hypothesized that cytomegalovirus pneumonitis contributes to adverse outcomes in the current antiviral era. We sought to define the impact of treated cytomegalovirus pneumonitis on bronchiolitis obliterans syndrome and survival in a large single-center cohort (n = 231) of consecutive patients undergoing lung transplantation from 2000 to 2004, all receiving short-course ganciclovir prophylaxis. METHODS: Transbronchial biopsies were performed at defined intervals with prospective cytomegalovirus immunostaining on every biopsy (n = 1,887). Cox proportional hazards models were used to assess the relationship between treated cytomegalovirus pneumonitis and clinical outcomes. MEASUREMENTS AND MAIN RESULTS: Forty-nine (21%) recipients developed cytomegalovirus pneumonitis a median of 106 days after transplantation. Treated cytomegalovirus pneumonitis within the first 6 months after transplantation significantly increased the risk for bronchiolitis obliterans syndrome (P = 0.001; hazard ratio, 2.19; 95% confidence interval, 1.36-3.51) and post-transplantation death (P = 0.02; hazard ratio, 1.89; 95% confidence interval, 1.11-3.23). This risk persisted when cytomegalovirus pneumonitis was considered as a time-dependent predictor as well as in multivariable models controlling for other risk factors. CONCLUSIONS: Cytomegalovirus pneumonitis affects more than 20% of lung transplant recipients. Despite treatment, it increases the risk for bronchiolitis obliterans syndrome and death. More effective preventive strategies for cytomegalovirus pneumonitis are needed to improve long-term outcomes after lung transplantation. |
| | |
Authors:
|
Laurie D Snyder; C Ashley Finlen-Copeland; W Jackson Turbyfill; David Howell; Daniel A Willner; Scott M Palmer |
Related Documents
:
|
18926405 - Is lymphocytic bronchiolitis a marker of acute rejection? an analysis of 2,697 transbro... 21114535 - Effects of anti-adhesive therapy on kidney biomarkers of ischemia reperfusion injury in... 9383235 - Spontaneous pneumomediastinum in a patient with bronchiolitis obliterans after bone mar... 19416775 - Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recip... 7624955 - Risk factors affecting second renal transplant outcome, with special reference to prima... 23530925 - Systematic kidney biopsies after acute allograft pyelonephritis. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-02-18 |
Journal Detail:
|
Title: American journal of respiratory and critical care medicine Volume: 181 ISSN: 1535-4970 ISO Abbreviation: Am. J. Respir. Crit. Care Med. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-18 Completed Date: 2010-07-01 Revised Date: 2011-08-01 |
Medline Journal Info:
|
Nlm Unique ID: 9421642 Medline TA: Am J Respir Crit Care Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1391-6 Citation Subset: AIM; IM |
Affiliation:
|
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. laurie.snyder@duke.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antiviral Agents / therapeutic use Bronchiolitis Obliterans / virology* Cohort Studies Cytomegalovirus Infections / drug therapy, virology* Female Ganciclovir / therapeutic use Humans Lung Transplantation / adverse effects* Middle Aged Pneumonia, Viral / drug therapy, virology* Postoperative Complications / virology Proportional Hazards Models Risk Factors Survival Analysis Syndrome Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
1P50-HL084917-01/HL/NHLBI NIH HHS; K24-091140-01//PHS HHS; KL2RR024127/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 82410-32-0/Ganciclovir |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Venous Thromboembolism and Risk of Idiopathic Interstitial Pneumonia: A Nationwide Study.
Next Document: Screening for Lymphangioleiomyomatosis with High-Resolution CT in Young, Nonsmoking Women Presenting...